ABSTRACT
BACKGROUND: Marek's disease is a chicken lymphoproliferative viral illness. As new viruses emerge, vaccination immunity is being broken and hence pathogenecity assessment and vaccine evaluation related to the pathogen is critical for developing vaccine immunity in the field. METHODS: An experimental investigation was conducted to determine the pathogenicity of field isolates against Marek's disease in antibody-free chicks and to assess the protective efficacy of the Marek's disease vaccination. The viral isolates in question were discovered during an outbreak investigation for a previous study. The pathogenicity and effectiveness trial used a complete random design. RESULTS: In the pathogenicity trial, chickens inoculated with Bishoftu and Mojo field isolate had lower body weight 77.7±3.757 and 78.15±1.95 g at 10 dpi, respectively, when compared to un-inoculated controls, 89.85±3.838 g at 10 dpi. Incidence of early mortality syndrome (35% and 25%), lymphoma (53.8% and 40%), and overall mortality (50% and 45%) between Bishoftu and Mojo isolates, respectively, was discovered. Vaccinations with Herpes virus of turkey challenged chickens were provided complete protection against Marek's disease. CONCLUSION: Based on the findings in pathogenecity assessment experimental trials, Bishoftu and Mojo isolates were designated as virulent Marek's disease viruses. Regular vaccinations with Herpes virus of turkey vaccine and supported by biosecurity measures in poultry farms are important to prevent the disease.
